SCHEMBL2844534

SCHEMBL2844534

CC(C)(NC(=O)c1c[nH]c2cc(NS(=O)(=O)c3cc(Cl)cc(Cl)c3)ccc12)C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 3/20 0.43
NR4A2 P43354 1/20 0.38
HSD11B1 P28845 1/20 0.38
SIRT6 Q8N6T7 2/20 0.37
IMPDH2 P12268 1/20 0.37
ESR1 P03372 1/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 2/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
ACLY P53396 3/20 0.36
POLB P06746 2/20 0.35
PGR P06401 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13941444 0.82 HTR6 (0.50) HTR6NR4A2IMPDH2ESR1CYP3A4
SCHEMBL2842004 0.80 NR4A2 (0.62) HTR6NR4A2SIRT6PSEN1PSEN2
SCHEMBL2845217 0.80 GPR27 (0.53) TP53
SCHEMBL2844537 0.78 HTR6 (0.43) HTR6NR4A2IMPDH2ESR1POLB
SCHEMBL3152853 0.78 HTR6 (0.51) HTR6NR4A2SIRT6IMPDH2ESR1
SCHEMBL19329440 0.72 HTR6 (0.41) HTR6NR4A2IMPDH2ESR1ACLY
SCHEMBL19329356 0.70 NR4A2 (0.50) HTR6NR4A2MAPTALDH1A1LMNA
SCHEMBL3304239 0.68 HTR6 (0.62) HTR6CYP3A4CYP2D6PSEN1PSEN2
SCHEMBL1576256 0.68 HTR6 (0.68) HTR6
SCHEMBL19329314 0.68 IMPDH2 (0.40) HTR6IMPDH2ESR1ACLYALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232312-B2 Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-07-31 US disclosed
US-20100130557-A1 SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130557-A1 SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS PYGL, PYGM, G6PC1 HTR6 2713/4885NR4A2 3961/4885HSD11B1 456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.